SCHEMBL16514550

SCHEMBL16514550

COc1cc(Nc2ncc3cccc(-c4cccc(C=CC(N)=O)c4)c3n2)ccc1N1CCN(C)CC1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.61
PAK1 Q13153 6/20 0.54
PKMYT1 Q99640 1/20 0.49
TNIK Q9UKE5 1/20 0.49
TNK2 Q07912 2/20 0.49
JAK2 O60674 4/20 0.48
BRD4 O60885 4/20 0.48
JAK3 P52333 2/20 0.48
JAK1 P23458 1/20 0.48
BRD2 P25440 1/20 0.48
BRD3 Q15059 1/20 0.48
BRDT Q58F21 1/20 0.48
FGFR1 P11362 1/20 0.47
KDR P35968 1/20 0.47
WEE1 P30291 1/20 0.46
KCNH2 Q12809 1/20 0.46
FLT3 P36888 1/20 0.46
ALK Q9UM73 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16513994 0.90 EGFR (0.63) EGFRPAK1TNK2JAK2BRD4
SCHEMBL16514436 0.90 EGFR (0.62) EGFRPAK1JAK2BRD4JAK3
SCHEMBL16513747 0.88 EGFR (0.61) EGFRPAK1PKMYT1JAK2BRD4
SCHEMBL16514587 0.84 FGFR1 (0.55) EGFRJAK2BRD4JAK3JAK1
SCHEMBL16514045 0.83 EGFR (0.79) EGFRPAK1JAK2BRD4JAK3
SCHEMBL16514319 0.83 FGFR1 (0.49) EGFRJAK2BRD4FGFR1KDR
SCHEMBL29847724 0.83 EGFR (0.79) EGFRPAK1JAK2BRD4JAK3
Maleic Acid SCHEMBL16514328 0.81 FGFR1 (0.56) EGFRPAK1JAK2BRD4FGFR1
Fumaric Acid SCHEMBL16514259 0.81 FGFR1 (0.56) EGFRPAK1JAK2BRD4FGFR1
SCHEMBL18527559 0.81 EGFR (0.50) EGFRJAK2BRD4JAK3JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3035936-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NeuPharma, Inc. (US) 2016-06-29 EP disclosed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 WO disclosed